You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

amoxicillin clavulanate susceptibility

Amoxicillin-clavulanate: Continues to demonstrate favourable susceptibility against common pathogens of community-acquired infections*

amoxicillin clavulanate key
SOAR: Shaping antibiotic confidence
amoxicillin clavulanate Aware Classification
amoxicillin clavulanate recurrent tonsillopharyngitis
amoxicillin clavulanate CAP pathogens
amoxicillin clavulanate pathogens

Augmentin Prescribing Information

augmentintin combine pi qr code

Augmentin safety information13

Contraindications :

  • In patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins. (UAE 457 mg)
  • In patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction. (UAE 457 mg)
  • In patients with known hypersensitivity to penicillins and cephalosporins or to any ingredient of Augmentin, as well as in patients who developed jaundice or hepatic dysfunction during previous Augmentin therapy. [457mg for (Oman, Qatar, Bahrain, Kuwait), & 1gm for all 5 GCC Countries]
  • Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients (ES for all 5 GCC Countries & 625 mg for UAE, Oman, Qatar, Bahrain)
  • History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam). (ES for all 5 GCC Countries & 625 mg for UAE, Oman, Qatar, Bahrain)
  • History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid. (ES for all 5 GCC Countries & 625 mg for UAE, Oman, Qatar, Bahrain)
  • Infectious mononucleosis, lymphocytic leukemia: Patients suffering from these diseases are particularly predisposed to exanthema formation during amoxicillin therapy. [457mg for (Oman, Qatar, Bahrain, Kuwait)]
  • Infectious mononucleosis, lymphatic leukaemia: when treated with amoxicillin, patients with these conditions are especially predisposed to skin rashes. (1gm for all 5 GCC Countries)

Undesirable Effects:

Mucocutaneous candidiasis, Diarrhoea, Nausea, vomiting

Kindly note that not all formulations are approved in all countries

References

  1. Pichichero ME. Pediatr Infect Dis J. 2000;19(9):911–6.
  2. Jamsheer A, Rafay AM, Daoud Z, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in the Gulf States. J Antimicrob Chemother 2016;71(Suppl 1):i45-i61.
  3. GSK - Survey of Antibiotic Resistance (SOAR) - AMR Industry Alliance. AMR Industry Alliance. Available at: https://www.amrindustryalliance.org/case-study/gsks-survey-of-antibiotic-resistance-soar. Accessed September 2023.
  4. Doern GV and Brecher SM. J Clin Microbiol. 2011;49(9_Suppl):S11–14.
  5. Survey of Antibiotic Resistance (SOAR) results: respiratory pathogen susceptibility. J Antimicrob Chemother. 2016;71(Suppl1):i3–i19.
  6. Survey of Antibiotic Resistance (SOAR) results 2: respiratory pathogen susceptibility. J Antimicrob Chemother. 2018;73(Suppl 5):v1–42.
  7. Survey of Antibiotic Resistance (SOAR) results 3: respiratory pathogen susceptibility. J Antimicrob Chemother. 2020;75(Suppl 1):i1–i111.
  8. World Health Organization. 22nd WHO Essential Medicines List, 2021. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.02. Accessed September 2023.
  9. Shoar, S. and Musher, D.M., (2020). Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia, 12, pp.1-10.
  10. Tinelli M, et al. Emerg Infect Dis. 2009;15(2): 250–57.
  11. Xiao N, et al. Infect Drug Resist. 2019;12:2495–503.
  12. Hirose Y, et al. Cell Rep. 2021;34(13):108924.
  13. Augmentin prescribing information.
  14. Clinical & Laboratory Standards Institute. M100, Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition. Available from: edaptivedocs.net. Last accessed 15 September 2023.

 

GSK does not recommend, endorse, or accept liability for the sites.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

Department of Pharmacovigilance & Drug Information
Drug Safety Center
Ministry of Health, Sultanate of Oman
Phone Nos. 0096822357687 / 0096822357690
Fax: 0096822358489
Email: pharma-vigil@moh.gov.om
Website: www.moh.gov.om

دائرة التيقظ و المعلومات الدوائية
مركز سلامة الدواء
وزارة الصحة, سلطنة عمان
هاتف: 0096822357687 / 0096822357690
0096822358489 :فاكس
pharma-vigil@moh.gov.om :البريد االكتروني
www.moh.gov.om : الموقع االكتروني

Trademarks are owned by or licensed to the GSK group of companies 

PM-RCH-ACA-WCNT-240003 Date of preparation: Jan 2025